FINWIRES · TerminalLIVE
FINWIRES

SHE:002252

4 stories mentioning SHE:002252Updated just now

Every FINWIRES story that references SHE:002252, newest first.

What's the latest news on SHE:002252?

Asia

Shanghai RAAS Blood Products Enters Phase 3 Trial for Hemophilia Injection

Shanghai RAAS Blood Products' (SHE:002252) SR604 injection for hemophilia entered phase 3 trials, according to a Thursday filing with the Shenzhen bourse.The phase 1/2 trials met pre-specified primary endpoints for hemophilia, the drug company said.The drug also conducted separate phase 2 trials for von Willebrand disease and for bleeding episodes in patients with congenital factor VII deficiency, the filing said.Shares in the drug company fell 1% during afternoon trading on Thursday.

SHE:002252
Asia

RAAS Blood Products Gets Chinese Drug Regulator's Proposal to Include SR604 Injection in Care Program - Extension Project; Shares Up 3%

Shanghai RAAS Blood Products (SHE:002252) received the recommendation of China's National Medical Products Administration to include its SR604 injection in the Care Program - Extension project, according to a Shenzhen bourse filing on Tuesday.One of the drug's targeted conditions is congenital factor VII deficiency.The project is a pilot program for encouraging the development of drugs for rare diseases.The Chinese blood products maker's shares rose 3% during the afternoon trade.

SHE:002252
Asia

Chinese Drug Regulator Accepts Clinical Trial Application of RAAS Blood Products' Unit for Protein C

China's National Medical Products Administration accepted the clinical trial application of Shanghai RAAS Blood Products' (SHE:002252) subsidiary, Guangxi RAAS Biopharmaceutical, for protein C, according to a Shenzhen bourse filing over the weekend.The product is used for the treatment of patients with congenital protein C deficiency, including the treatment of acute thrombosis and prevention of thrombosis.

SHE:002252
Asia

Shanghai RAAS Blood Products Advances Blood Clotting Disorder Drug to Phase Two

Shanghai RAAS Blood Products (SHE:002252) initiated a second-phase clinical trial for SR604 injection targeting congenital coagulation factor VII deficiency.The study will evaluate multiple-dose efficacy of SR604 levels administered every four weeks, according to a Thursday filing with the Shenzhen bourse.Shares of the blood products maker slid 1% in recent trade.

SHE:002252

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:002252 in your portfolio
WheelAI
WheelAI
Analyze SHE:002252 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:002252